<h3>Key Takeaways:</h3>
<ul>
<li>Contract roles in life sciences offer higher pay, flexibility, and exposure to high-impact, specialist projects.</li>
<li>Contract employment can provide professional development opportunities, with opportunities to remain embedded in the same organization for years.</li>
<li>In life sciences, contracting has become a practical model for project-based, specialized work such as R&amp;D, clinical trials, and regulatory operations.</li>
<li>Many U.S. life science organizations are adopting a hybrid workforce model, combining permanent employees with contractors.</li>
</ul>
<hr>
<h2>The changing structure of work in life sciences</h2>
<p>The employment model within the life sciences sector is shifting to accommodate both continuity and specialized expertise. Businesses are increasingly blending permanent and contract workforces to meet evolving project demands, particularly in areas such as biotechnology, clinical development, and regulatory affairs.</p>
<p>According to the <a href="https://www.bls.gov/careeroutlook/2025/article/fastest-growing-industry-sector.htm">U.S. Bureau of Labor Statistics (BLS)</a>, employment in professional, scientific, and technical services is projected to grow 10.5% from 2023 to 2033. The top five fastest-growing occupations include data scientists (#1), information security analysts, medical and health service managers, computer and information research scientists, and operations research analysts.</p>
<p>CBRE states that &lsquo;<a href="https://www.cbre.com/insights/books/us-life-sciences-outlook-2025/five-positive-forces-unfolding-in-2025"><em>more people than ever are employed in the life science industry</em></a>&rsquo;, with record-high employment in biotechnology R&amp;D, especially in cell and gene therapy. Between January and October , biotech R&amp;D companies experienced a 3.7% increase in employment, resulting in a record workforce of 303,000.</p>
<p>This continued into 2025, when U.S. life sciences employment reached an all-time high <a href="https://www.cbre.com/insights/reports/us-life-sciences-talent-trends-2025">of 2.1 million in March</a>, and long-term trends remain positive, with employment roughly growing by <a href="https://intuitionlabs.ai/pdfs/us-biotech-job-market-2025-trends-data-analysis.pdf">79% over the past two decades, outpacing the 8% growth of the overall job market</a>.</p>
<p>Such demand creates competition for roles, and alongside this, employers&rsquo; expectations have increased, with many now prioritizing candidates with specialized skills and adaptability, and increasingly turning to contract professionals to deliver specialist expertise when and where it&rsquo;s needed.</p>
<p>There&rsquo;s:</p>
<ul>
<li>A growing need for technical proficiency in areas such as cell and gene therapy, AI-enabled diagnostics, and data-driven clinical trials. Cell and gene therapy funding alone <a href="https://intuitionlabs.ai/articles/life-sciences-job-market-2025">reached $15.2 billion in 2025, a 30% increase from 2023</a>.</li>
<li>Increased emphasis on cross-functional experience, especially in regulatory strategy, clinical operations, and digital platforms.</li>
<li>Opportunities to contribute to short-term, high-impact projects throughout contract engagements.</li>
</ul>
<p>With this in mind, having a clear understanding of contract roles can help you make informed decisions about your next steps. It&rsquo;s a valuable way to position yourself for opportunities that match your strengths and career goals in a fast-changing industry.</p>
<h2>What are the main differences between contract and permanent employment?</h2>
<p>The difference between these two arrangements lies primarily in duration, compensation structure, and employment status.</p>
<ul>
<li><strong>Contract roles </strong>typically cover a specific project or business need, often within defined timeframes. Many contractors in life sciences are employed on a W2 basis, meaning they&rsquo;re taxed as standard employees and may receive employer-sponsored benefits. Contractors are brought in for their specialist expertise and can remain within the same company for extended periods, contributing to long-term projects and objectives.</li>
<li><strong>Permanent roles </strong>offer ongoing employment with a fixed salary, access to employer-sponsored benefits, and inclusion in long-term workforce and development programs. Employees are typically aligned to broader organizational goals and career pathways within a single company.</li>
</ul>
<p>In practice, contract and permanent positions can complement one another. Many U.S. companies use integrated workforce models to scale quickly for initiatives such as <a href="https://redbock.com/expertise/clinical/">clinical trial phases</a> or <a href="https://redbock.com/expertise/regulatory-and-compliance/">regulatory submissions</a>, without committing to permanent headcount growth.</p>
<h2>What are the advantages of contract work?</h2>
<p>Contracting in life sciences appeals to professionals seeking independence, variety, and exposure to cutting-edge technologies. Contractors often command higher hourly rates than salaried employees, reflecting the premium placed on specialized skills and project urgency.</p>
<p>Contract roles enable professionals to:</p>
<ul>
<li><strong>Be flexible</strong> in their work; having the ability to select projects, clients, and timelines provides greater control over one&rsquo;s career path.</li>
<li><strong>Broaden their experience and portfolio</strong> by working across multiple projects and companies, which exposes them to varied systems, methodologies, working relationships, and business culture, expanding their technical and interpersonal capabilities.</li>
<li><strong>Have career agility</strong> by aligning themselves with specific scientific or technical areas, gaining practical experience faster than may be possible in a single company.</li>
<li><strong>Job security</strong><strong>and consistent compensation</strong>, even during fluctuations in project volume. Most contracts are extended beyond the initial contract period as client&rsquo;s needs increase and other projects become available.</li>
<li><strong>Employee benefits</strong>, including healthcare coverage, paid leave, and retirement/pension contributions.</li>
<li><strong>Defined career pathways</strong>, supported by internal training and leadership development programs.</li>
<li><strong>Organizational belonging</strong>, with opportunities to influence culture and strategy over time.</li>
</ul>
<h2>Does contract still offer career development?</h2>
<p>&ldquo;Development&rdquo; can be defined in different ways, and ultimately contracting supports either definition. For some, development means technical breadth, gaining exposure and direct experience with a range of systems, technologies, and operational frameworks.</p>
<p>For others, development means progression within a more corporate structure, for example, leading teams, driving departmental strategies, and influencing operational direction.</p>
<p>Contracting supports both paths by providing exposure to varied challenges and opportunities across multiple projects and organizations.</p>
<h2>Why are life science companies increasingly employing contractors?</h2>
<p>Recent data highlights a consistent pattern of workforce diversification within life sciences. The found that 94% of CEOs intend to increase headcount within three years. Still, many cite the replacement of retiring employees and the availability of specialized skills as major challenges, as many key capabilities are learned on the job.</p>
<p><a href="https://kpmg.com/xx/en/our-insights/value-creation/global-ceo-outlook-survey/life-sciences.html">Another trend explored by KPMG in their 2025 report</a>, is that 86% of global life sciences CEOs report moderate-to-hire <a href="https://redbock.com/news/life-sciences-m-a-trends-in-2026/">interest for M&amp;A</a>, and 73% expect their organizations to operate in hybrid workforce models within three years. Both of these trends increase reliance on contract workers, particularly during periods of integration, pipeline expansion, or digital transformation.</p>
<p><a href="https://redbock.com/news/how-is-AI-pushing-the-life-science-industry-forward/">AI adoption</a> also continues to affect hiring strategies. According to <a href="https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html">Deloitte&rsquo;s 2026 Life Sciences Outlook</a>, 78% of biopharma and medtech leaders expect AI to play a central role in organizational change, and nearly a third plan to use AI tools or training to increase workforce productivity. While this change can be seen across the board, it demands professionals with skills in AI, data, automation, and digital platform expertise, new skills that businesses can&rsquo;t yet source internally.</p>
<p>From clinical trials to regulatory submissions, many initiatives have defined timelines and resource needs, making contract support a practical solution. Contract professionals help bridge skills gaps by providing targeted, technical support without the onboarding and training time associated with permanent roles.</p>
<p>Contract engagements also allow companies to align workforce costs with project cycles. For example, a biopharmaceutical firm may engage regulatory consultants during a submission phase and adjust staffing once approval is complete.</p>
<h2>What legal and financial considerations apply in the U.S.?</h2>
<p>Contract employees receive W2 income, with payroll taxes automatically withheld and access to employer-sponsored benefits. They are also covered under employment laws such as the Fair Labor Standards Act (FLSA) and the Occupational Safety and Health Act (OSHA).</p>
<p>Professionals considering contract work might need to consult tax advisors to determine whether to operate as a sole proprietor, LLC, or as a W2 employee. For those in the life sciences sector, working with a specialized consulting partner such as Redbock can simplify contract administration, compliance, and client engagement.</p>
<h2>What should you consider before choosing contract work?</h2>
<p>The decision should match both your career objectives and personal priorities. Consider:</p>
<ul>
<li>Do you enjoy variety and new challenges?</li>
<li>Are you looking to accelerate your career growth and earning potential?</li>
<li>How important are flexibility and independence in your career progression?</li>
</ul>
<h2>Explore Opportunities with Redbock</h2>
<p>Redbock is a specialized <a href="https://redbock.com/">life sciences consulting agency</a> focused on contract placements. We support professionals across clinical operations, regulatory affairs, R&amp;D, and beyond, connecting them with high-impact projects that align with their expertise and goals.</p>
<p>Ready to explore your next role in life sciences? <a href="https://redbock.com/contact/">Contact our team today</a> and speak with a specialist.</p>
<hr>
<h2>FAQs</h2>
<h3>Can contract jobs lead to permanent employment?</h3>
<p>Yes. Many contract roles can convert to permanent positions, especially when the company has ongoing needs, and the contractor performs well. Conversion depends on budget, headcount plans, and whether the role was designed as contract-to-hire.</p>
<h3>What skills are most in demand for life sciences professionals today?</h3>
<p>Employers are prioritizing AI literacy, bioinformatics, automation, advanced therapeutic expertise, regulatory knowledge, and strong cross-functional communication.</p>
<h3>Why are contractors important for life sciences?</h3>
<p>Companies rely on contractors to fill specialized skill gaps and scale quickly in response to project peaks. This flexibility helps organizations adapt to fast-moving scientific and market demands.</p>
<h3>How does Redbock support life science companies with contract professionals?</h3>
<p>Redbock is an expert in <a href="https://redbock.com/">life sciences consulting and resourcing</a>, with a focus on contract engagements. We provide individual specialists, dedicated project teams, and functional service provision (FSP) models to help organizations grow efficiently and access niche expertise.</p>
<h3>What types of contract opportunities does Redbock offer?</h3>
<p>Redbock connects life science professionals with high-impact contract roles across a range of disciplines including engineering, clinical, regulatory, biometrics, project management, drug safety and medical affairs. <a href="https://redbock.com/expertise/">Learn more about our expertise</a>.</p>

Pros of Contract Employment: Is This the Right Path for You?

<h3>Key Takeaways:&nbsp;</h3>
<ul>
<li>Life sciences M&amp;A is rebounding to a more favorable environment in 2026, with higher-value, strategic deals offsetting lower overall deal volume.</li>
<li>The&nbsp;<a href="https://www.drugpatentwatch.com/blog/beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars/">patent cliff</a> is acting as a catalyst for big pharma to focus on acquiring growth-focused assets and late-stage pipelines, rather than relying on long-risk R&amp;D.</li>
<li><a href="https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html">AI, digital transformation, and consumer-centric care</a> are reshaping deals, with many transactions targeting AI-enabled platforms and data-driven innovation.</li>
<li>Resourcing and workforce planning are becoming more critical as talent scarcity and M&amp;A-driven attrition/displacement puts pressure on companies to fill roles.</li>
</ul>
<hr>
<p>The life sciences industry is no stranger to peaks and troughs in mergers and acquisitions (M&amp;A) trends, particularly in the post-pandemic era. However, after a <a href="https://www.reuters.com/markets/deals/dealmakers-see-rebound-after-global-ma-volumes-hit-decade-low-2023-12-21/">dip in 2023</a>, factors seem to be influencing a more optimistic, favorable M&amp;A environment.</p>
<p>As we continue to move through 2026, industry stakeholders need to understand the factors influencing these deals and the way they impact the supply of highly-skilled talent in the life sciences sector.</p>
<h2>The Current Life Sciences M&amp;A Outlook</h2>
<p>Despite volatility due to evolving global trade policies and higher interest rates, the total deal value in the life sciences industry reached <a href="https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify">$372bn in 2025</a> (an increase of 47% year-over-year), with the Americas accounting for <a href="https://www.pwc.com/gx/en/services/deals/trends/health-industries.html">73% of the total</a> and dominating in terms of deal value.</p>
<p>Though overall deal volume is lower, there has been a shift instead to higher-impact, strategic transactions instead, driven by life sciences companies seeking to overcome the drawn-out timelines and high-risk nature of R&amp;D.</p>
<p>Between biotechnology, pharmaceutical, and medtech companies, the contribution to M&amp;A&rsquo;s uptick has been relatively equal (about 30% of deal volume). Biopharmaceuticals in particular have been characterized by growth-focused M&amp;A &mdash; between 2020 and 2025, <a href="https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify">76% of deals were focused on growth</a>, compared to 34% a decade ago. MedTech has entered into 2026 with a healthier M&amp;A environment due to <a href="https://pmcf.com/perspectives/2026-medtech-ma-outlook-strengthens-as-buyers-prioritize-innovation-and-resilience/">improved financing conditions and sector resilience</a>.</p>
<p>Pipeline pressures continue to influence life sciences M&amp;A trends, as businesses look to navigate evolving regulatory requirements causing a <a href="https://www.drugpatentwatch.com/blog/beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars/">&ldquo;patent cliff&rdquo;</a> for large pharma, in which a revenue risk of $300bn in annual branded drug revenue is at risk of being lost to generic and biosimilar competition between 2025-2030.</p>
<h2>Key M&amp;A Life Sciences Deal Activity</h2>
<ul>
<li><strong>Johnson &amp; Johnson acquired Intra-Cellular Therapies, Inc </strong>in Q2 2025 for $14.6bn, with particular emphasis on CAPLYTA&reg;, a schizophrenia and bipolar disorder drug.</li>
<li><strong>Novartis acquired Avidity Biosciences </strong>in Q1 2026 for $12bn, aiming to strengthen Novartis&rsquo; late-stage neuroscience pipeline.</li>
<li><strong>Pfizer acquired obesity biotech Metsera </strong>for up to $10bn in November 2025, following a surprise bid from Novo Nordisk, with additions to their pipeline including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist.</li>
<li><strong>Merck &amp; Co. acquisition of Verona Pharma</strong> announced in Q4 2025, valued at $10bn and boosting Merck&rsquo;s respiratory portfolio, centered on Ohtuvayre, a maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD).</li>
<li><strong>Novo Nordisk acquired Akero Therapeutics </strong>in October 2025 for up to $5.2bn, and its metabolic dysfunction-associated steatohepatitis (MASH) candidate efruxifermin.</li>
</ul>
<p>These acquisitions represent the significant reshaping of big pharma portfolios, specifically in relation to the &ldquo;patent cliff&rdquo;, alongside the rebound of global deal activity towards larger-scale, high-impact deals &mdash; as with <a href="https://redbock.com/news/life-sciences-m-a-outlook/">2025 mergers and acquisitions of note</a>, addressing unmet medical needs is still a key focus of many transactions.</p>
<h2>The Trends Impacting Life Sciences M&amp;A</h2>
<h3>Patent cliffs in biologics pharma driving diversification</h3>
<p>The patent cliff wave has continued to impact life sciences mergers and acquisitions, with a cluster of widely prescribed small-molecule drugs set to lose protection in 2026 across primary care, cardiology, and immunology, pushing companies to favor lower-cost versions to reduce revenue risk.</p>
<p>A <a href="https://www.sec.gov/Archives/edgar/data/310158/000162828025017867/formars202410-k.pdf">2024 annual report by Merck</a> noted the pressure points facing Keytruda, a prescription immunotherapy medication. It expects U.S. sales to decline in January 2028 with government pricing under the Inflation Reduction Act, then further decline after a loss of exclusivity due to the expiration of the U.S. compound patent in 2028. This is just one example of how originators attempt to hold share when a biologic is on the approach to losing exclusivity.</p>
<h3>Consumer-centric, Tech-enabled care</h3>
<p>M&amp;A is one of the fastest ways to catalyze digital innovation, and the deals that stand out in the future will be those backed by <a href="https://www.pwc.com/gx/en/services/deals/trends/health-industries.html">AI-enhanced productivity</a>, differentiated data, evidence-backed innovation, and clear pathways to long-term value creation.</p>
<p>An example of the high-innovation shift in life sciences M&amp;A was one of medtech&rsquo;s largest ever AI deals in <a href="https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-acquire-intelerad-advancing-cloud-enabled">GE HealthCare&rsquo;s $2.3bn acquisition of Intelerad</a>, aimed at accelerating GE HealthCare&rsquo;s D3 strategy (disease-focused devices enabled by digital and AI).</p>
<h3>Therapeutic Focus That Sets Standards of Care</h3>
<p>Areas such as cardiometabolic, CNS, oncology, and immunology are still maintaining a strong pace of innovation which continues to drive financial and strategic interest for capital allocation. According to a <a href="https://kpmg.com/us/en/media/news/2026-hcls-investment-outlook.html">KPMG study</a>, oncology and immunology are anticipated to be the most competitive areas for acquisition by biopharma professionals.</p>
<p>In pharma in 2025, oncology was at the top of dealmaking with <a href="https://www.deloitte.com/us/en/industries/life-sciences-health-care/articles/mergers-and-acquisitions-trends-survey-life-sciences.html">30% of $120bn deals</a>, with buyers focusing on immune cell therapies, multi-specific antibodies, and radioligand technologies, while neurology, rare disease, and cardiovascular drove $36bn in transactions.</p>
<p>Technological innovation and digital transformation are also key areas across subsectors, with 90% of medical devices respondents expecting <a href="https://kpmg.com/us/en/media/news/2026-hcls-investment-outlook.html">10% or more of deals to incorporate artificial intelligence or machine learning</a>. <a href="https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html">AI-driven analytics, robotics platforms, and connected-care ecosystems</a> are prioritized targets, acting as deal catalysts.</p>
<h3>Portfolio Optimization</h3>
<p>In 2025, a number of key markers have impacted deal activity and the shaping of portfolios, including:</p>
<ul>
<li>A shift toward acquisitions of single or smaller portfolios of clinical assets</li>
<li>An emphasis on acquiring mature, high-growth technologies in medtech</li>
<li>The absence of mega-deals, particularly in healthcare, driving a shift toward operational optimization and risk management</li>
</ul>
<p>In short, acquisitions are becoming more strategic and specific to address gaps, further innovation, and strengthen growth after a period of economic uncertainty.</p>
<h2>What to Expect in Life Sciences M&amp;A For the Rest of 2026</h2>
<p>The outlook for life sciences M&amp;A activity in 2026 is favorable &mdash; a combination of fast transformation and a surge of higher-value deals make 2026 a year of capitalizing on innovation. In a KPMG study, <a href="https://www.deloitte.com/us/en/industries/life-sciences-health-care/articles/mergers-and-acquisitions-trends-survey-life-sciences.html">67% of respondents expected more deals in 2026 than 2025</a>, with a higher percentage anticipating growth in deal volume rather than fewer transactions.</p>
<p>A few of the trends we expect to see include:</p>
<ul>
<li><strong>Urgency to restock pipelines: </strong>The patent cliff will drive pharma companies to double their efforts to develop or acquire the next generation of top-selling medications.</li>
<li><strong>Strong financial capacity for M&amp;A: </strong>Industry leaders should have considerable financial resources to make more strategic acquisitions, given that in 2025, <a href="https://kpmg.com/kpmg-us/content/dam/kpmg/pdf/gated/2026/hcls-investment-outlook-2026.pdf">23 companies had a combined cash and debt capacity of nearly $1.4 trillion</a>.</li>
<li><strong>Artificial intelligence: </strong>AI is an emerging catalyst for M&amp;A activity, as AI-powered platforms transform drug discovery, clinical trial management, and administrative operations, with many looking to fully integrate these capabilities.</li>
<li><strong>Regulatory changes: </strong>The broader life sciences regulatory environment is driving the portfolio shift towards high-value, strategic assets rather than relying on internal R&amp;D pipelines, and deal complexities and timelines are likely to be impacted by regulatory changes.</li>
</ul>
<h2>What This Means for Resourcing and Workforce Planning in Life Sciences</h2>
<p>An optimistic M&amp;A outlook in the life sciences industry goes hand-in-hand with a more competitive market for finding resourcing solutions and workforce planning. The demand created by the M&amp;A market is influencing a demand for specialized support to secure those with regulatory, tech-enabled, and commercial skillsets.</p>
<p>During M&amp;A changeovers, attrition and displacement can cause turbulence as employees consider their options and overall job security, increasing turnover rates and creating further strain on companies during an already challenging time.</p>
<p>Scarcity of talent is driving more strategic workforce planning, particularly as the life sciences industry continues to experience periods of highs and lows in growth of employment. Whilst <a href="https://www.cbre.com/insights/reports/us-life-sciences-talent-trends-2025">U.S. life sciences employment reached a record of 2.1 million in March 2025</a>, it fell measurably in April 2025, as <a href="https://4413123.fs1.hubspotusercontent-na1.net/hubfs/4413123/Insight%20Reports%20and%20Surveys/202601%20-%202026%20Employment%20Outlook%20Report/BioSpace%20-%202026%20Employment%20Outlook%20Report.pdf">high competition and layoffs</a> are still impacting the industry, making partnering with a consultancy firm highly advantageous for businesses looking to be more strategic and adaptable.</p>
<h2>Partner With Us: Your Leading Life Sciences Consulting Firm</h2>
<p>Redbock is a leading , providing FSP and contract resourcing solutions that help businesses through challenging M&amp;A transition periods. We align customized solutions to your business post-merger, ensuring that our solutions help you onboard and retain skilled professionals when you need them most to thrive in the ever-changing, competitive life sciences market.</p>
<p>If your organization is looking for highly skilled life sciences consultants to support your business during a period of change, <a href="https://redbock.com/contact/">contact us today</a> to navigate the transition and future changes with confidence.</p>
<hr>
<h2>Frequently Asked Questions: Life Sciences M&amp;A</h2>
<h3>What top trends are shaping life sciences M&amp;A activity in 2026?</h3>
<p>The top trends impacting life sciences M&amp;A activity in 2026 are: the patent cliffs, driving more strategic and high-quality deals to fill pipeline gaps; digital transformation, with an emphasis on deals backed by AI-enhanced productivity; therapeutic focus areas continuing to drive deals, including cardiometabolic, CNS, oncology, and immunology.</p>
<p>Regulatory and policy changes are also catalyzing portfolio restructuring, and deal activity is rooted in strategy rather than simply just buying assets to meet these new demands and developments.</p>
<h3>Which life sciences companies have been most involved in recent M&amp;A deals?</h3>
<ul>
<li><strong>Johnson &amp; Johnson:</strong> Acquired Intra-Cellular to strengthen its neuroscience portfolio.</li>
<li><strong>Merck:</strong> Bought Verona Pharma for respiratory growth, adding Ohtuvayre to its lineup.</li>
<li><strong>Pfizer:</strong> Acquired Metsera to build their portfolio in the obesity and cardiometabolic pipeline.</li>
<li><strong>Novartis:</strong> Agreed to acquire Avidity Biosciences to improve its RNA drug-delivery capability and strengthen its late-stage neuroscience pipeline.</li>
</ul>
<h3>What are the most common post-merger integration challenges in life sciences?</h3>
<p>Some of the biggest post-merger integration challenges in life sciences are operational disruption, cultural misalignment, failure to meet financial targets, IT integration difficulties, loss of key talent, and low morale, according to a <a href="https://www.travelers.com/resources/business-industries/life-sciences/life-sciences-mergers-acquisitions">Travelers report</a>.</p>
<h3>What should I look for when selecting a life sciences consulting partner?</h3>
<p>A good <a href="https://redbock.com/about-us/">life sciences consulting partner</a> should bring extensive industry experience, regulatory and compliance knowledge, and sector-specific awareness of the challenges in the current life sciences hiring market to the table. Supports should be tailored to your specific subsector and practical processes (e.g., integrating teams, or supporting day-one execution after a deal).</p>

Expertise

Biometrics

Clinical

Drug Safety & Medical Affairs

Engineering

Program & Project Management

Quality

Regulatory & Compliance

Market leading insights in resourcing solutions

Pros of Contract Employment: Is This the Right Path for You?

Life Sciences M&A Trends in 2026